Skip to main content
OpenTrials
Completed

NCT Number: NCT00485108

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty

The type of anti-inflammatory medication used post selective laser trabeculoplasty (SLT) may have an impact on the intra-ocular pressure (IOP) lowering effect of SLT. This study will evaluate the IOP lowering effect of SLT following the topical administration of one of the following: prednisolone 1%, ketorolac 0.5% or artificial tears.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Open Angle Glaucoma Exfoliation Syndrome Eye Diseases Glaucoma Glaucoma, Open-Angle Iris Diseases Ocular Hypertension Pseudoexfoliation Glaucoma Uveal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Queen's University

Kingston, Ontario, Canada

About this study

Patients who have been chosen to undergo SLT for glaucoma will be randomized to receive one of prednisolone 1%, ketorolac 0.5% or artificial tears four times a day for 5 days following administration of the laser treatment. The IOP will be measured at various time points following SLT: 1 hour, 2 days, 1 week, 1 month, 3 months, 6 months, and 1 year.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • primary open angle glaucoma, pseudo exfoliation glaucoma

Exclusion criteria

  • previous incisional glaucoma surgery

Treatment and study plan

Prednisolone 1%

Drug

eye drop once in each eye treated, 4 times / day for 5 days post-laser

Ketorolac 0.5%

Drug

eye drop once in each eye treated, 4 times / day for 5 days post-laser

Other names: Acular

Artificial Tears (Methyl cellulose drops)

Drug

eye drop once in each eye treated, 4 times / day for 5 days post-laser

Other names: Refresh Tears

Primary outcomes

  1. Intraocular pressure lowering effect

    Time frame: 1 hour, 2 days, 1 month, 3 months, 6 months and 1 year

Secondary outcomes

  1. intraocular pressure elevation

    Time frame: 1 hour, 2 days, 1 month

Sponsors and collaborators

Lead sponsor

Queen's University

Other

Collaborators

  • Glaucoma Research Society of Canada
  • Pfizer

Registry information

Official study title

Anti-inflammatory Therapy Following Selective Laser Trabeculoplasty (SLT): A Randomized, Masked, Placebo Controlled Study

Important dates

Study start
2007
Primary completion
2009
Study completion
2014
First posted
Jun 12, 2007
Registry last updated
Sep 23, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.